MA37506B1 - Utilisations thérapeutiques de protéines de facteur de croissance des fibroblastes 21 - Google Patents

Utilisations thérapeutiques de protéines de facteur de croissance des fibroblastes 21

Info

Publication number
MA37506B1
MA37506B1 MA37506A MA37506A MA37506B1 MA 37506 B1 MA37506 B1 MA 37506B1 MA 37506 A MA37506 A MA 37506A MA 37506 A MA37506 A MA 37506A MA 37506 B1 MA37506 B1 MA 37506B1
Authority
MA
Morocco
Prior art keywords
growth factor
fibroblast growth
therapeutic uses
factor proteins
proteins
Prior art date
Application number
MA37506A
Other languages
English (en)
Other versions
MA37506A1 (fr
Inventor
Yanfei Linda Ma
Rovira Armando Rafael Irizarry
Vincent Louis Reynolds
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48483225&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA37506(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MA37506A1 publication Critical patent/MA37506A1/fr
Publication of MA37506B1 publication Critical patent/MA37506B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La présente invention concerne des utilisations thérapeutiques de protéines de facteur de croissance des fibroblastes 21 (fgf21) humain.
MA37506A 2012-05-15 2013-05-09 Utilisations thérapeutiques de protéines de facteur de croissance des fibroblastes 21 MA37506B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261646974P 2012-05-15 2012-05-15
US201361786939P 2013-03-15 2013-03-15
PCT/US2013/040275 WO2013173158A1 (fr) 2012-05-15 2013-05-09 Utilisations thérapeutiques de protéines de facteur de croissance des fibroblastes 21

Publications (2)

Publication Number Publication Date
MA37506A1 MA37506A1 (fr) 2016-01-29
MA37506B1 true MA37506B1 (fr) 2017-03-31

Family

ID=48483225

Family Applications (1)

Application Number Title Priority Date Filing Date
MA37506A MA37506B1 (fr) 2012-05-15 2013-05-09 Utilisations thérapeutiques de protéines de facteur de croissance des fibroblastes 21

Country Status (21)

Country Link
US (1) US20150141335A1 (fr)
EP (1) EP2852398A1 (fr)
JP (1) JP2015522539A (fr)
KR (1) KR20150002801A (fr)
CN (1) CN104302311A (fr)
AU (1) AU2013263188A1 (fr)
BR (1) BR112014028413A2 (fr)
CA (1) CA2869320A1 (fr)
CL (1) CL2014002846A1 (fr)
CO (1) CO7131381A2 (fr)
EA (1) EA201491856A1 (fr)
HK (1) HK1202800A1 (fr)
IL (1) IL235482A0 (fr)
MA (1) MA37506B1 (fr)
MX (1) MX2014013913A (fr)
PE (1) PE20142432A1 (fr)
PH (1) PH12014502537A1 (fr)
SG (1) SG11201407655TA (fr)
TN (1) TN2014000409A1 (fr)
WO (1) WO2013173158A1 (fr)
ZA (1) ZA201407532B (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102077721B1 (ko) 2011-07-01 2020-02-14 엔지엠 바이오파마슈티컬스, 아이엔씨. 대사성 장애 및 질환의 치료를 위한 조성물, 용도 및 방법
EP3798228A1 (fr) 2012-11-28 2021-03-31 NGM Biopharmaceuticals, Inc. Compositions et procédés pour le traitement de troubles métaboliques et de maladies
US9290557B2 (en) 2012-11-28 2016-03-22 Ngm Biopharmaceuticals, Inc. Compositions comprising variants and fusions of FGF19 polypeptides
US9273107B2 (en) 2012-12-27 2016-03-01 Ngm Biopharmaceuticals, Inc. Uses and methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
ES2915851T3 (es) 2012-12-27 2022-06-27 Ngm Biopharmaceuticals Inc Péptidos quiméricos de FGF19 para usar en el tratamiento de trastornos de ácidos biliares
CA2927592C (fr) 2013-10-28 2020-08-18 Ngm Biopharmaceuticals, Inc. Variants de fgf-19 pour le traitement d'un cancer ou d'une tumeur fgf-19-dependant
EP3097122B9 (fr) 2014-01-24 2020-11-11 NGM Biopharmaceuticals, Inc. Anticorps liant beta-klotho 2 et leurs procédés d'utilisation
WO2015183890A2 (fr) 2014-05-28 2015-12-03 Ngm Biopharmaceuticals, Inc. Méthodes et compositions pour le traitement de maladies et de troubles métaboliques
US10456449B2 (en) 2014-06-16 2019-10-29 Ngm Biopharmaceuticals, Inc. Methods and uses for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
WO2016039339A1 (fr) * 2014-09-08 2016-03-17 国立大学法人大阪大学 Agent de prévention ou traitement de la maladie démyélinisante
IL251834B2 (en) 2014-10-23 2023-09-01 Ngm Biopharmaceuticals Inc Pharmaceutical compositions containing peptide variants and methods of using them
WO2016073855A1 (fr) 2014-11-07 2016-05-12 Ngm Biopharmaceuticals, Inc. Procédés de traitement de troubles liés à l'acide biliaire et prédiction de la sensibilité clinique au traitement de troubles liés aux acides biliaires
US10800843B2 (en) 2015-07-29 2020-10-13 Ngm Biopharmaceuticals, Inc. Beta klotho-binding proteins
CA3082794A1 (fr) 2015-11-09 2017-05-18 Ngm Biopharmaceuticals Inc. Methodes de traitement de troubles associes aux acides biliaires
EP3503882A4 (fr) 2016-08-26 2020-07-29 NGM Biopharmaceuticals, Inc. Méthodes de traitement de cancers et de tumeurs à médiation assurée par le facteur de croissance des fibroblastes 19
CN108324928B (zh) * 2018-03-05 2020-09-08 哈尔滨医科大学 重组人成纤维细胞生长因子-5在促骨折愈合中的应用
WO2021139744A1 (fr) 2020-01-11 2021-07-15 Beijing Ql Biopharmaceutical Co., Ltd. Conjugués de protéines de fusion du glp-1 et du fgf21

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104163864B (zh) * 2007-03-30 2017-08-01 Ambrx公司 经修饰fgf‑21多肽和其用途
AR087973A1 (es) * 2011-10-04 2014-04-30 Lilly Co Eli Variantes del factor 21 del crecimiento de fibroblastos

Also Published As

Publication number Publication date
WO2013173158A1 (fr) 2013-11-21
KR20150002801A (ko) 2015-01-07
ZA201407532B (en) 2016-05-25
IL235482A0 (en) 2014-12-31
HK1202800A1 (en) 2015-10-09
EA201491856A1 (ru) 2015-03-31
AU2013263188A1 (en) 2014-10-16
SG11201407655TA (en) 2014-12-30
EP2852398A1 (fr) 2015-04-01
JP2015522539A (ja) 2015-08-06
BR112014028413A2 (pt) 2017-11-07
CO7131381A2 (es) 2014-12-01
CL2014002846A1 (es) 2015-01-30
PH12014502537A1 (en) 2015-01-21
MX2014013913A (es) 2015-02-17
PE20142432A1 (es) 2015-01-22
CN104302311A (zh) 2015-01-21
CA2869320A1 (fr) 2013-11-21
TN2014000409A1 (en) 2015-12-21
MA37506A1 (fr) 2016-01-29
US20150141335A1 (en) 2015-05-21

Similar Documents

Publication Publication Date Title
MA37506A1 (fr) Utilisations thérapeutiques de protéines de facteur de croissance des fibroblastes 21
EA201390060A1 (ru) Аннелированные пиримидины и триазины и их применение для лечения и/или профилактики сердечно-сосудистых заболеваний
BR112015009924A2 (pt) formulações de proteína imunoglobulina de domínio variável duplo estáveis
TR201910959T4 (tr) Elektromanyetik radyasyonun insan irisine uygulanması.
EA202090516A3 (ru) Бициклические гетероциклы в качестве ингибиторов fgfr
PE20150201A1 (es) Proteinas del factor 21 de crecimiento del fibroblasto
EA201591616A1 (ru) Трифторметил-замещенные аннелированные пиримидины и их применение
EA201791693A1 (ru) Гетеродимерные иммуноглобулины
UY34721A (es) Anticuerpos anti-hla-b*27 y usos de éstos.
GT201400057A (es) 3-pirmidin-4-il-oxazolidin-2-onas como inhibidores de la idh mutante
EA201491811A1 (ru) АНТИ-LgR5 АНТИТЕЛА И ИММУНОКОНЪЮГАТЫ
EA201590962A1 (ru) Новые соединения
JO3357B1 (ar) مركبات إيميدازوبيروليدينون
UY34602A (es) ?Derivados de bencimidazolil- e imidazopiridinil-metilamina?
ECSP12012349A (es) Agentes inductores de apoptosis contra el cáncer y de enfermedades inmunes y autoinmunes
ECSP12012348A (es) Agentes inductores de apoptosis contra el cáncer y de enfermedades inmunes y autoinmunes
EA201491766A1 (ru) Соединения для лечения спинальной мышечной атрофии
MA34521B1 (fr) Polypeptides de relaxine modifiés et leurs utilisations
IN2014DN11201A (fr)
EA201492040A1 (ru) Бициклически замещённые урацилы и их применение
MD3355919T2 (ro) Terapie combinată cu utilizarea inhibitorilor factorului de creștere și diferențiere uman 15 (GDF-15) și a blocanților punctelor de control imunitar
EA201490790A1 (ru) Пептидные конъюгаты агониста рецептора гастрина и глюкагон подобного пептида 1
EA201290744A1 (ru) Имидазо[1,2-b][1,2,4]триазины в качестве c-met ингибиторов
FR3003173B1 (fr) Substituts osseux greffes par des peptides mimetiques de la proteine humaine bmp-2.
EA201390955A1 (ru) Слитый белок robo1-fc для применения в лечении гепатокарциномы